Daniel Howard

A landmark 5GWh agreement between Fox ESS and OSW isn't just about storage; it’s a blueprint for a decentralized, resilient, and renewable-powered grid.

A landmark deal for CEL-SCI’s cancer drug Multikine in Saudi Arabia isn't just about a new market; it’s a case study in national ambition and biotech finance.

By upgrading to the OTCQX market, junior explorer Tesoro Gold isn't just changing its ticker; it's tapping a vital financial system to fund a massive Chilean gold project.

Jazz Pharma's lung cancer drug Zepzelca fails a key trial, raising regulatory questions. Yet its strength in another setting reveals a complex drug development system.

Kymera Therapeutics reports promising data for KT-621, a first-in-class oral drug that removes a key inflammatory protein, not just block it.

For decades, patients with a rare autoimmune anemia faced a cycle of steroids and relapse. New data on a targeted therapy may finally offer a durable solution.

With a record-breaking IPO and over $1.2 billion raised this year, Parabilis Medicines is attacking diseases once thought untouchable. But can its Helicon platform deliver?

Methodist Healthcare Ministries is building Ministry Park, a 16-acre development that combines affordable patient lodging with public green space, pioneering a new model for social impact.

Andersen Consulting partners with HeadMind Partners, leveraging deep European expertise in cybersecurity and AI to bolster its global transformation services.

Rugs.com's new app uses augmented reality to solve online shopping's biggest challenge: uncertainty. It's a look into the new baseline for digital retail.

A major funding round positions GPS Renewables to accelerate India's transition to cleaner fuels, turning waste into a cornerstone of national energy security.

With shareholder backing and a major acquisition nearly complete, IsoEnergy is building a global uranium powerhouse to meet soaring nuclear energy demand.

A new report reveals generative AI is ignoring decade-long SEO winners like Chegg, favoring brands like Khan Academy. The lesson? Authority is the new algorithm.

A market set to triple, driven by gene-level therapies, promises a revolution for children with rare epilepsies. But can our systems deliver this hope?

IncQuery's new AI tools promise to fuse speed with rigor, embedding an AI moderator directly into the secure workflows of consulting and private equity.

DuPont now powers its US healthcare plants with 100% renewables, a key move in a carbon-heavy sector. But a look behind the certificates reveals a complex strategy.

Inclusion in the Russell Microcap® Index is a milestone, but the real story is how the firm is engineering growth in the booming digital-first media landscape.

A silent disease affects 54 million Americans and is set to cost $95 billion by 2030. Now, 33 states are taking action against the osteoporosis epidemic.

While state budgets struggle, a local credit union is funding classroom innovation from the ground up, proving small investments can rebuild our educational systems.

AI platform FINNY's new enterprise deal with wealth giant Mercer Advisors reveals the industry's new playbook: using centralized tech to scale client acquisition.